Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial symbols : Pfe save search
Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS® Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Published: 2024-03-12 (Crawled : 12:30) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.21%
H: 0.11%
C: -1.06%
adcetris positive trial
ViiV Healthcare presents phase I clinical trial findings of a cabotegravir long-acting injectable investigational formulation allowing at least four months between doses
Published: 2024-03-04 (Crawled : 21:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -1.09%
H: 0.61%
C: -1.56%
trial
Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer
Published: 2024-02-14 (Crawled : 14:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.15%
H: 0.59%
C: 0.37%
ARVN | $34.78 1.43% 1.41% 940K
|
Health Technology
|
| O: -1.09%
H: 5.61%
C: 4.49%
first breast cancer trial therapeutics advanced
Enthera Pharmaceuticals Appoints Lisa M. Olson as CEO and Announces Clinical Trial Progress with Ent001
Published: 2024-01-23 (Crawled : 12:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.46%
H: 0.74%
C: -0.04%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: -0.07%
H: 0.0%
C: 0.0%
ceo pharmaceuticals trial
Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions - December 8, 2023
Published: 2023-12-08 (Crawled : 16:00) - biospace.com/
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -1.29%
H: 0.4%
C: 0.4%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.07%
H: 1.1%
C: 0.45%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.19%
H: 0.35%
C: 0.2%
kisqali breast risk novartis
Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program
Published: 2023-12-05 (Crawled : 19:00) - globenewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.0%
H: 1.07%
C: -1.03%
ARVN | $34.78 1.43% 1.41% 940K
|
Health Technology
|
| O: 5.35%
H: 26.96%
C: 24.13%
ibrance program trial
Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15
Published: 2023-12-04 (Crawled : 21:00) - globenewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.24%
H: 1.34%
C: -0.41%
vla15 disease vaccine valneva trial
Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity
Published: 2023-12-01 (Crawled : 22:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -4.92%
H: 1.48%
C: -0.21%
obesity topline results
Pfizer Announces New England Journal of Medicine Publication on Group B Streptococcus (GBS) Maternal Vaccine Candidate
Published: 2023-07-19 (Crawled : 22:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.28%
H: 0.99%
C: 0.28%
candidate vaccine publication group
Carrick Therapeutics Announces Clinical Trial Collaboration with Arvinas and Pfizer to Evaluate Samuraciclib and Vepdegestrant Combination
Published: 2023-07-06 (Crawled : 14:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.71%
H: 0.19%
C: -1.57%
ARVN | $34.78 1.43% 1.41% 940K
|
Health Technology
|
| O: -2.06%
H: 0.0%
C: -3.96%
collaboration trial therapeutics
Phase 3 Studies of Pfizer’s Novel Antibiotic Combination Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options
Published: 2023-06-01 (Crawled : 17:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.26%
H: 0.24%
C: -0.26%
hope treatment infections
Pfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial
Published: 2023-05-30 (Crawled : 11:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.64%
H: 0.0%
C: -0.94%
positive trial results
IDEAYA Expands Clinical Trial Collaboration and Supply Agreements with Pfizer to Support Registrational Trial Evaluating Darovasertib and Crizotinib Combination in First-Line Metastatic Uveal Melanoma
Published: 2023-05-16 (Crawled : 10:00) - prnewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.38%
H: 0.59%
C: -0.03%
IDYA | $37.1 -1.38% -1.4% 730K
|
Health Technology
|
| O: -0.42%
H: 1.21%
C: -0.93%
melanoma collaboration trial
TILT Biotherapeutics Announces First Patient Dosed in Phase I Solid Tumors Trial Assessing Oncolytic Adenovirus TILT-123 in Combination with Checkpoint Inhibitor
Published: 2023-05-15 (Crawled : 10:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.13%
H: 0.16%
C: -0.38%
tilt-123 adenovirus tumors trial
Novartis Kisqali® Phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in broad population of patients with early breast cancer
Published: 2023-03-27 (Crawled : 06:00) - globenewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.37%
H: 0.2%
C: -0.79%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 6.51%
H: 1.75%
C: 1.4%
kisqali breast cancer novartis trial
Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors
Published: 2023-03-16 (Crawled : 12:20) - biospace.com/
PYXS | $4.155 -8.28% -9.03% 670K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 7.46%
C: 7.46%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.55%
H: 1.07%
C: 0.77%
pyx-201 tumors trial phase 1
Pfizer and Valneva Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15
Published: 2023-02-17 (Crawled : 08:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.14%
H: 1.12%
C: 0.75%
vla15 valneva candidate disease vaccine trial update
Pfizer Announces Positive TALZENNA® and XTANDI® Combination Data from Phase 3 TALAPRO-2 Study
Published: 2023-02-16 (Crawled : 16:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.39%
H: 0.07%
C: -0.46%
talzenna positive study
HIV Clinical Trials Market Research Report by Phase, Study Design, Sponsor, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19
Published: 2022-12-26 (Crawled : 13:20) - prnewswire.com
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
| Email alert
Add to watchlist
NVO | $122.71 -0.03% 0.17% 5M
|
Health Technology
| Email alert
Add to watchlist
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
| Email alert
Add to watchlist
SYNH | $42.98 0.0% 7.4M
|
Health Services
| Email alert
Add to watchlist
ICLR | $288.32 -1.2% -1.21% 640K
|
Health Technology
| Email alert
Add to watchlist
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
| Email alert
Add to watchlist
covid-19 trials research global report hiv impact study market
Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial (VERITAC)
Published: 2022-11-22 (Crawled : 12:20) - globenewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.33%
H: 1.88%
C: 1.53%
ARVN | $34.78 1.43% 1.41% 940K
|
Health Technology
|
| O: 1.04%
H: 0.02%
C: -6.5%
arv-471 expansion trial
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.